Nasdaq

Microinvasive Glaucoma Surgery with the OMNI® Surgical System is Associated with Diminished Diurnal IOP Fluctuations, a Significant, Independent Risk Factor for Glaucoma ...

12-Month OMNI data from the prospective, multicenter GEMINI clinical trial show statistically significant postoperative reductions in mean IOP and suppression of daily IOP fluctuations MENLO PARK, ...
Seeking Alpha

Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and ...

Clinical results demonstrate long-term efficacy of the OMNI® Surgical System for primary open-angle glaucoma and support use of TearCare® technology as a primary treatment for dry eye disease. OMNI ...
AOL

UnitedHealthcare Adds Sight Sciences OMNI System To Covered Glaucoma Surgery Procedures

Sight Sciences Inc. (NASDAQ:SGHT) on Tuesday announced that UnitedHealthcare has updated its Glaucoma Surgical Treatments policy to cover goniotomy, trabeculotomy, canaloplasty (ab interno), and ...
Healio

VIDEO: Omni system with cataract surgery shows long-term IOP reduction

Please provide your email address to receive an email when new articles are posted on . The study enrolled patients with mild to moderate primary open-angle glaucoma who underwent canaloplasty and ...
Benzinga.com

Sight Sciences' Cataract Surgery Tech Shows Consistent Lowering Of Eye Pressure, Medication Use

Sight Sciences Inc (NASDAQ:SGHT) published two-year results of the so-called "Romeo" study of the OMNI Surgical System.